Date  |
|
| Jun 30, 2020 |
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises |
| Jun 24, 2020 |
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series |
| May 11, 2020 |
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results |
| May 4, 2020 |
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer |
| Apr 23, 2020 |
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study |
| Apr 8, 2020 |
Important Update For CEL-SCI Corporation Annual Meeting of Shareholders |
| Mar 30, 2020 |
CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders |
| Mar 26, 2020 |
CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal |
| Mar 24, 2020 |
CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million |
| Mar 23, 2020 |
CEL-SCI Announces Bought Deal Offering |